分子肿瘤委员会:国际肺癌研究协会共识声明
该共识由国际肺癌研究协会发起,采用改良德尔菲法,37名国际专家经三轮调查和在线会议形成共识,共识阈值≥75%同意。共识明确了分子肿瘤委员会(MTB)的必备成员、病例选择、会议频率不超过14天、报告标准化、治疗排序和绩效评估框架。
要点
- MTB必备成员包括分子诊断专家(分子生物学家或病理学家)和瘤种特异性肿瘤内科医生。
- 病例选择应反映机构专长和病例量,新成立的MTB应审阅选择性较低的病例以积累经验。
- 报告应标准化,包含临床病理数据、生物标志物结果和建议,治疗选项按证据等级排序。
核心结论
- 这些MTB共识推荐适用于所有瘤种,尽管由肺癌和分子专家制定并由国际肺癌研究协会发起。
- 共识为MTB实施、报告标准化、病例选择和质量评估提供了结构化框架,旨在标准化实践并弥合个性化癌症诊疗中的专业差距。
研究设计与样本
- 采用改良德尔菲法,涉及37名国际专家,进行三轮调查和在线会议,共识定义为同意率≥75%。
主要发现
- 专家组确定分子生物学家或病理学家(具备分子诊断专长)和瘤种特异性肿瘤内科医生为MTB不可或缺的成员。
- 病例选择应反映机构专长和病例量,较新的MTB应审阅选择性较低的病例以积累经验。
- 建议定期召开会议,以避免从结果可获得到讨论的延迟超过14天。
- 报告应标准化,包括临床病理数据(肿瘤特征、治疗史)、生物标志物发现(检测结果、样本详情)和建议(治疗、重新检测、遗传咨询)。
- 治疗选项应按可操作性的证据等级排序,并可包括当地不可用的选项;绩效评估应考虑基于MTB输入的患者管理变化和匹配治疗率。
关键数值与推荐
- 共识定义为同意率≥75%。
- MTB必备成员包括分子生物学家或病理学家(具备分子诊断专长)和瘤种特异性肿瘤内科医生。
- 建议定期召开会议,以避免从结果可获得到讨论的延迟超过14天。
- 报告应标准化,包括临床病理数据、生物标志物发现和建议。
- 治疗选项应按可操作性的证据等级排序,并可包括当地不可用的选项。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Molecular tumor boards (MTBs) are multidisciplinary meetings of specialists dedicated to analyzing biomarker test results to provide personalized treatment recommendations. However, global disparities in the successful implementation of MTBs exist, driven by unequal access to molecular diagnostics and supportive multidimensional expertise. OBJECTIVE: To establish recommendations for MTB implementation, outline practical frameworks for their operation, and address disparities in expertise and resources between new and established MTBs. DESIGN: A modified Delphi method involved 37 international experts in three survey rounds and online meetings, with consensus defined as more than or equal to 75% agreement. RESULTS: The panel identified a molecular biologist or pathologist with expertise in molecular diagnostics and tumor-specific medical oncologists as indispensable MTB members. Case selection should reflect institutional expertise and volume, with newer MTBs reviewing less selected cases to gain experience. Regular meetings are advised to avoid delays beyond 14 days from result availability to discussion. Reporting should be standardized to include clinicopathologic data (tumor characteristics, treatment history), biomarker findings (testing results, sample details), and recommendations (treatment, retesting, genetic counseling). Treatment options should be ranked by the level of evidence for actionability and may include options not available locally. Performance evaluation should consider changes in patient management based on MTB input and matched therapy rates. CONCLUSIONS: These MTB consensus recommendations are applicable across tumor types, despite being developed by lung cancer and molecular specialists and initiated by the International Association for the Study of Lung Cancer. They provide a structured framework for MTB implementation, report standardization, case selection, and quality assessment, aiming to standardize practice and address gaps in expertise for personalized cancer care.
引用
- Aldea M, Rotow JK, Arcila M, et al. Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2025. PMID: 40633839. doi:10.1016/j.jtho.2025.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。